RxDoctor Payments Data

Ashley Couvillion

Family · Belle Chasse, LANPI 1124652235

Payments from drug & device makers

$2,154in general payments, 2019–2025

Across 79 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$445
  • Lilly USA, LLC$224
  • Revance Therapeutics, Inc.$144
  • GSK$143
  • Dermavant Sciences, Inc.$125
  • Teva Pharmaceuticals USA, Inc.$123
  • plus $949 from 19 others

What the payments were for

  • Food & beverage$2,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,154 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$26,428
JardianceEmpagliflozin13$20,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,145
FarxigaDapagliflozin Propanediol11$7,961
XareltoRivaroxaban11$6,904
SymbicortBudesonide/Formoterol Fumarate12$2,942
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,513
Gabapentin55$1,039
Duloxetine Hcl29$707
Atorvastatin Calcium97$695
Levocetirizine Dihydrochloride24$557
Albuterol Sulfate HfaAlbuterol Sulfate28$521
Hydroxyzine Hcl31$505
Fluticasone Propionate36$375
Ezetimibe15$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$26,42820 claims
Boehringer IngelheimJardiance$66$20,13413 claims
GSKTrelegy Ellipta$143$13,14516 claims
AstraZenecaFarxiga, Symbicort$13$10,90423 claims
Johnson & JohnsonXarelto$115$6,90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.

Other family in Belle Chasse

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →